Cardlytics (CDLX) PT Raised to $130 as JPMorgan Reiterates Neutral Rating
Tweet Send to a Friend
JPMorgan analyst Doug Anmuth raised the price target on Cardlytics (NASDAQ: CDLX) to $130.00 (from $110.00) after the company reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
